Biphenyl Dimethyl Dicarboxylate participated in clinical trials phase III in the patients with chronic liver disease. In addition, the drug was studied in phase III clinical trials after laparoscopic cholecystectomy. The use of BDD in patients with cholecystitis was expected to inhibit elevated liver enzyme levels and to maintain liver function.
MedKoo Cat#: 150068
Name: Biphenyl Dimethyl Dicarboxylate
CAS#: 792-74-5
Chemical Formula: C16H14O4
Exact Mass: 270.0892
Molecular Weight: 270.28
Elemental Analysis: C, 71.10; H, 5.22; O, 23.68
The following data is based on the product molecular weight 270.28 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
